Medicine
Ergomar Sublingual 2 mg tablet
Ergomar Sublingual 2 mg tablet is a prescription medicine containing Ergotamine for oral use, marketed by Pangea Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°- 25°C (68° - 77°F), excursions permitted to 15° - 30°C (59° -…
Key facts
- Active ingredient (INN)
- Ergotamine
- Brand
- Ergomar Sublingual
- Strength
- 2 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 blister pack, 2 blister pack
- Marketing authorisation holder
- Pangea Pharmaceuticals
- Manufacturer
- Pangea Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°- 25°C (68° - 77°F), excursions permitted to 15° - 30°C (59° - 86°F). Protect from light and heat.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CA02 Ergotamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 February 2025
- Identifiers
- RxCUI 1293862, 1293864DailyMed set ID a9582fdb-7ddd-4f69-aa7a-66247cdb8c92NDC 81279-104Application ANDA087693
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 3 tablet in 1 blister pack | 81279-104-03 | Pangea Pharmaceuticals | 3 February 2025 |
| 2 blister pack in 1 carton / 10 tablet in 1 blister pack | 81279-104-20 | Pangea Pharmaceuticals | 3 February 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 13 January 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ergotamine is an ergotamine derivative indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia".. It is available as tablets for oral use. MedsAcross supplies Ergotamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ErgotamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Ergomar Sublingual prescribing information (Pangea Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Ergomar Sublingual 2 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.